Novo Nordisk reports 22% weight loss with amycretin
2 days ago · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the …
Novo Nordisk's next-gen obesity treatment hits target in early …
6 days ago · Novo said that patients on a high dose of the injectable form of the drug, called amycretin, lost 22% of their weight after 36 weeks, when analyzing the effects if all people …
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
6 days ago · Novo Nordisk unveiled topline Phase Ib/IIa data Friday for its next-generation obesity treatment amycretin, which elicited up to 22% weight-loss in adults with overweight or obesity.. …
Novo Nordisk stock pops on phase I data for new weight-loss drug …
6 days ago · Novo Nordisk's stock rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results.The new drug, amycretin, …
Novo Nordisk shares pop on early-stage weight loss drug trial …
6 days ago · The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t …
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection …
What is CagriSema? The next-gen Ozempic weight loss drug
Nov 18, 2024 · Novo Nordisk (NVO) — the company credited with ushering in the current weight-loss drug revolution when it launched its blockbuster diabetes treatment Ozempic in 2017 — is …
Experimental Oral Drug Shows 'Remarkable' Weight Loss, Novo Nordisk …
Sep 23, 2024 · In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second …
Novo Nordisk affirms 25% weight-loss expectation for experimental drug ...
Nov 6, 2024 · Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its …